Ascendis Pharma AS
$ 243.91
-2.85%
31 Jul - close price
- Market Cap 16,468,393,000 USD
- Current Price $ 243.91
- High / Low $ 252.46 / 243.30
- Stock P/E 29.23
- Book Value 8.94
- EPS 8.59
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE 0.33 %
- 52 Week High 282.15
- 52 Week Low 173.33
About
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Analyst Target Price
$307.92
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASND
2026-07-31 03:11:48
This article provides a valuation analysis of Ascendis Pharma A/S (ASND), highlighting its current valuation score of 7.87 within the Biotechnology & Medical Research industry. It notes the P/E ratio is 36.18, which is below its recent high but significantly above its recent low. The article also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
2026-07-30 12:10:55
This page provides financial information for Ascendis Pharma A/S ADR (A1SN34) traded on BMFBOVESPA. It focuses on the "Price to book forward" metric and lists the company's trading status as "Market closed" with "No trades." The content is primarily a financial data page from TradingView.
2026-07-30 03:10:56
This article provides a technical analysis of Ascendis Pharma A/S (ASND), focusing on its price momentum, support and resistance levels, and various technical indicators. The stock's current price momentum score is 3.21, ranking it low in the Biotechnology & Medical Research industry, and it is trading within a range suitable for swing trading. Technical indicators such as MACD, RSI, and moving averages present mixed signals, with more moving averages indicating a 'buy' compared to 'sell' signals.
2026-07-29 05:10:28
Ascendis Pharma A/S (ASND) has a current financial score of 8.41, ranking 45 out of 385 in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company's latest quarterly revenue surged by 153.66% year-over-year to $289.14 million, with net profit increasing by 790.64%. Despite strong growth, some detailed financial data for various metrics have not yet been disclosed.
2026-07-28 16:44:00
This article provides a price-driven insight for Ascendis Pharma A/s (ASND), highlighting divergent sentiment across all time horizons and an exceptional 27.2:1 risk-reward setup. It details institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide potential trading decisions for investors.
2026-07-27 23:41:51
Ascendis Pharma A/S (NASDAQ: ASND) generated a total revenue of $845.80 million last year, with its Pharmaceutical segment being the largest contributor at $812.73 million. A significant portion of this revenue, $616.64 million, came from the United States market. This indicates a substantial increase in the Pharmaceutical segment's performance compared to the previous year's $393.35 million.
